BR0209319A - Tratamento ou profilaxia de rejeição de enxerto de célula produtora de insulina - Google Patents
Tratamento ou profilaxia de rejeição de enxerto de célula produtora de insulinaInfo
- Publication number
- BR0209319A BR0209319A BR0209319-7A BR0209319A BR0209319A BR 0209319 A BR0209319 A BR 0209319A BR 0209319 A BR0209319 A BR 0209319A BR 0209319 A BR0209319 A BR 0209319A
- Authority
- BR
- Brazil
- Prior art keywords
- insulin
- prophylaxis
- graft rejection
- producing cell
- cell graft
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 6
- 102000004877 Insulin Human genes 0.000 title abstract 3
- 108090001061 Insulin Proteins 0.000 title abstract 3
- 229940125396 insulin Drugs 0.000 title abstract 3
- 206010052779 Transplant rejections Diseases 0.000 title abstract 2
- 238000011321 prophylaxis Methods 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 229940124073 Complement inhibitor Drugs 0.000 abstract 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 abstract 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000004074 complement inhibitor Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 150000002596 lactones Chemical class 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29706901P | 2001-06-08 | 2001-06-08 | |
| PCT/EP2002/006278 WO2002100148A2 (en) | 2001-06-08 | 2002-06-07 | Treatment or prophylaxis of insulin-producing cell graft rejection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0209319A true BR0209319A (pt) | 2004-07-20 |
Family
ID=23144725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0209319-7A BR0209319A (pt) | 2001-06-08 | 2002-06-07 | Tratamento ou profilaxia de rejeição de enxerto de célula produtora de insulina |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US20030003099A1 (https=) |
| EP (1) | EP1429845B1 (https=) |
| JP (1) | JP4476623B2 (https=) |
| CN (1) | CN1524002A (https=) |
| AT (1) | ATE424893T1 (https=) |
| AU (1) | AU2002320828B2 (https=) |
| BR (1) | BR0209319A (https=) |
| CA (1) | CA2445605A1 (https=) |
| DE (1) | DE60231522D1 (https=) |
| ES (1) | ES2322442T3 (https=) |
| IL (1) | IL158384A0 (https=) |
| NO (1) | NO20035434D0 (https=) |
| NZ (1) | NZ529044A (https=) |
| PL (1) | PL364359A1 (https=) |
| PT (1) | PT1429845E (https=) |
| RU (1) | RU2003136730A (https=) |
| WO (1) | WO2002100148A2 (https=) |
| ZA (1) | ZA200307893B (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2267993T3 (es) * | 2001-02-22 | 2007-03-16 | Novartis Ag | Uso de agentes de migracion acelerada de linfocitos para la fabricacion de un medicamento para el tratamiento de la funcion retardada del injerto. |
| ES2528362T3 (es) * | 2004-05-14 | 2015-02-09 | Alexion Pharmaceuticals, Inc. | Prolongación de la supervivencia de un aloinjerto por inhibición de la actividad del complemento |
| CN101014329B (zh) * | 2004-07-16 | 2010-09-08 | 杏林制药株式会社 | 用于对器官或组织的移植的排异反应或骨髓移植的移植物抗宿主反应预防或治疗的药物组合物 |
| KR20140095109A (ko) * | 2004-11-29 | 2014-07-31 | 노파르티스 아게 | Ｓ１ｐ 수용체 효능제의 투여 용법 |
| US20080206240A1 (en) * | 2005-02-08 | 2008-08-28 | Shreeram Aradhye | Antilymphocyte Antibody Induction |
| US20090191218A1 (en) | 2005-05-11 | 2009-07-30 | Fengchun Li | DNA Vaccines And Methods For The Prevention Of Transplantation Rejection |
| DE602006015373D1 (de) * | 2005-05-11 | 2010-08-19 | Univ Loma Linda | Zusammensetzungen und Verfahren zur Prävention und Behandlung von immunvermittelten Entzündungskrankheiten |
| KR101346527B1 (ko) * | 2005-12-15 | 2013-12-31 | 미쓰비시 타나베 파마 코퍼레이션 | 아민 화합물 및 그 의약 용도 |
| RS53864B1 (sr) * | 2006-03-02 | 2015-08-31 | Alexion Pharmaceuticals, Inc. | Produžavanje preživljavanja alografta inhibiranjem aktivnosti komplementa |
| EP2069375B1 (en) * | 2006-09-28 | 2012-03-28 | Loma Linda University | Apoptotic cell-mediated transfection of mammalian cells with interfering RNA |
| WO2009099174A1 (ja) | 2008-02-07 | 2009-08-13 | Kyorin Pharmaceutical Co., Ltd. | アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤 |
| EP3332801B1 (en) * | 2008-03-12 | 2023-09-13 | Loma Linda University | Dna vaccines and methods for the prevention of transplantation rejection |
| HUE033168T2 (en) | 2008-03-17 | 2017-11-28 | Actelion Pharmaceuticals Ltd | Dosage regimen for selective SIP1 receptor agonist |
| CA2743232C (en) * | 2008-11-11 | 2015-12-29 | Novartis Ag | Crystalline forms of fingolimod hcl |
| MX2011004924A (es) * | 2008-11-11 | 2011-05-30 | Novartis Ag | Sales de fingolimod. |
| EP2455876A3 (en) * | 2009-06-30 | 2013-01-30 | Lifescan Scotland Limited | System and method for diabetes management |
| JP5654587B2 (ja) * | 2009-06-30 | 2015-01-14 | ライフスキャン・インコーポレイテッドＬｉｆｅｓｃａｎ，Ｉｎｃ． | 基礎インスリン療法を算出する分析物試験方法及び装置 |
| ES2631610T3 (es) * | 2009-09-29 | 2017-09-01 | Lifescan Scotland Limited | Dispositivo y método de ensayo de analito para la gestión de la diabetes |
| WO2011106029A1 (en) * | 2010-02-25 | 2011-09-01 | Lifescan Scotland Limited | Analyte testing method and system with high and low blood glucose trends notification |
| US11680273B2 (en) | 2011-09-23 | 2023-06-20 | Loma Linda University | Treatment of autoimmune diseases |
| US10813987B2 (en) | 2011-09-23 | 2020-10-27 | Loma Linda University | Method for inducing a tolerogenic immune response |
| CN114306643A (zh) * | 2021-11-30 | 2022-04-12 | 中国科学院昆明动物研究所 | 一种恒河猴免疫抑制模型的构建方法及在car-t细胞植活上的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5604229A (en) * | 1992-10-21 | 1997-02-18 | Yoshitomi Pharmaceutical Industries, Ltd. | 2-amino-1,3-propanediol compound and immunosuppressant |
| US5679546A (en) * | 1993-09-24 | 1997-10-21 | Cytomed, Inc. | Chimeric proteins which block complement activation |
| WO1995023512A1 (en) * | 1994-03-03 | 1995-09-08 | Alexion Pharmaceuticals, Inc. | Terminal complement inhibitor fusion genes and proteins |
| GB9624038D0 (en) * | 1996-11-19 | 1997-01-08 | Sandoz Ltd | Organic compounds |
| JPH1180026A (ja) * | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
| ES2267993T3 (es) * | 2001-02-22 | 2007-03-16 | Novartis Ag | Uso de agentes de migracion acelerada de linfocitos para la fabricacion de un medicamento para el tratamiento de la funcion retardada del injerto. |
-
2002
- 2002-06-07 ES ES02754637T patent/ES2322442T3/es not_active Expired - Lifetime
- 2002-06-07 WO PCT/EP2002/006278 patent/WO2002100148A2/en not_active Ceased
- 2002-06-07 CA CA002445605A patent/CA2445605A1/en not_active Abandoned
- 2002-06-07 IL IL15838402A patent/IL158384A0/xx unknown
- 2002-06-07 PL PL02364359A patent/PL364359A1/xx not_active Application Discontinuation
- 2002-06-07 RU RU2003136730/15A patent/RU2003136730A/ru not_active Application Discontinuation
- 2002-06-07 PT PT02754637T patent/PT1429845E/pt unknown
- 2002-06-07 AT AT02754637T patent/ATE424893T1/de active
- 2002-06-07 AU AU2002320828A patent/AU2002320828B2/en not_active Ceased
- 2002-06-07 CN CNA028098498A patent/CN1524002A/zh active Pending
- 2002-06-07 DE DE60231522T patent/DE60231522D1/de not_active Expired - Lifetime
- 2002-06-07 NZ NZ529044A patent/NZ529044A/en unknown
- 2002-06-07 BR BR0209319-7A patent/BR0209319A/pt not_active IP Right Cessation
- 2002-06-07 US US10/164,755 patent/US20030003099A1/en not_active Abandoned
- 2002-06-07 EP EP02754637A patent/EP1429845B1/en not_active Expired - Lifetime
- 2002-06-07 JP JP2003502981A patent/JP4476623B2/ja not_active Expired - Fee Related
-
2003
- 2003-10-09 ZA ZA200307893A patent/ZA200307893B/en unknown
- 2003-12-05 NO NO20035434A patent/NO20035434D0/no not_active Application Discontinuation
-
2006
- 2006-03-09 US US11/372,383 patent/US20060153842A1/en not_active Abandoned
-
2008
- 2008-04-22 US US12/107,726 patent/US20080199465A1/en not_active Abandoned
-
2011
- 2011-06-06 US US13/154,106 patent/US20110236382A1/en not_active Abandoned
-
2013
- 2013-12-05 US US14/098,179 patent/US20140093502A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PL364359A1 (en) | 2004-12-13 |
| US20060153842A1 (en) | 2006-07-13 |
| EP1429845A2 (en) | 2004-06-23 |
| NZ529044A (en) | 2008-03-28 |
| JP4476623B2 (ja) | 2010-06-09 |
| CA2445605A1 (en) | 2002-12-19 |
| RU2003136730A (ru) | 2005-05-20 |
| US20080199465A1 (en) | 2008-08-21 |
| EP1429845B1 (en) | 2009-03-11 |
| DE60231522D1 (de) | 2009-04-23 |
| AU2002320828B2 (en) | 2006-02-02 |
| US20110236382A1 (en) | 2011-09-29 |
| US20140093502A1 (en) | 2014-04-03 |
| WO2002100148A3 (en) | 2004-04-22 |
| US20030003099A1 (en) | 2003-01-02 |
| IL158384A0 (en) | 2004-05-12 |
| WO2002100148A2 (en) | 2002-12-19 |
| ZA200307893B (en) | 2004-09-06 |
| CN1524002A (zh) | 2004-08-25 |
| ATE424893T1 (de) | 2009-03-15 |
| PT1429845E (pt) | 2009-06-15 |
| ES2322442T3 (es) | 2009-06-22 |
| NO20035434D0 (no) | 2003-12-05 |
| JP2004534788A (ja) | 2004-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0209319A (pt) | Tratamento ou profilaxia de rejeição de enxerto de célula produtora de insulina | |
| CA1237986A (en) | Rapid method of interrupting the narcotic addiction syndrome | |
| BR0012136A (pt) | Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos | |
| KR950002785A (ko) | 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜 | |
| RU99128072A (ru) | Новая форма s-омепразола | |
| NZ514574A (en) | Novel method of treatment | |
| BR9908030A (pt) | Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado | |
| ATE383875T1 (de) | Prophylaktische oder therapeutische mittel gegen entzündliche erkrankungen des verdauungstraktes enthaltend antagonistische il-6 rezeptor antikörper | |
| UA86344C2 (ru) | Способ лечения сосудистых заболеваний | |
| EP0871488A4 (en) | ANAL-SAFE SYNERGY THROUGH SIMULTANEOUS ADMINISTRATION OF SUBANAL-SIDED CANES FROM A MU OPIOID ANAGONIST AND A KAPPA - 2 OPIOID ANAGONIST | |
| SE9800550D0 (sv) | A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof | |
| HU9603228D0 (en) | Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies | |
| KR930702000A (ko) | 노년기 치매, 식용항진, 편두통, 또는 식용불량의 치료를 위한 파로세틴의 사용 | |
| BRPI0406484A (pt) | Método de inibição da ocorrência de uma ou mais das seguintes condições: a proliferação de monócitos/macrófagos; ou a proliferação de células do músculo liso; ou a expressão de receptores de cd36; ou a absorção de lipoproteìna de baixa densidade - ldl oxidada, método de alìvio de sintomas de tratamento ou prevenção de aterosclerose; de diabetes; do mal de alzheimer, método de inibição da ocorrência da formação de placas no sistema vascular, método de alìvio da inflamação associada a ocorrência de uma ou de mais das seguintes condições: a proliferação de monócitos, a proliferação de células do músculo liso, a expressão de ldl oxidadas ou de receptor descontaminante, composição farmacêutica, uso de uma quantidade eficaz de um ou mais derivados ou fosfato de um ou mais agentes de transferência de elétrons conjuntamente com um veìculo ou um diluente apropriado, uso de uma quantidade eficaz de um ou mais derivados de fosfato de (alfa)-tocoferol conjuntamente com um veìculo ou um diluente apropriado e uso de uma quantidade eficaz de um ou mais derivados de fosfato de um ou mais agentes de transferência de elétrons selecionados do grupo que consiste em fosfato mono-tocoferila, fosfato de di-tocoferila e as misturas destes conjuntamente com um veìculo ou um diluente apropriado | |
| NO20055880L (no) | Memantin orale doseringsformer | |
| BR9709838A (pt) | Regime de administração que fornece um perfil de plasma no sangue de um inibidor de h+,k+-atpase composição farmacêutica oral uso da mesma e de inibidor h+,k+-atpase e processos para melhorar a inibição de secreção de ácido gástrico e o efeito terapêutico no tratamento de perturbações gastrintestinais e para receber um perfil estendido de plasma de um inibidor de h+,k+-atpase | |
| TR200101163T2 (tr) | Safra suyu ikameli fenil-alkenoilguanidinler, üretim yöntemleri, kullanımları | |
| BR0200246A (pt) | Tratamento de combinação para a depressão | |
| BR0211855A (pt) | Medicamento e método para tratamento e melhoria da qualidade restauradora do sono | |
| BR0212167A (pt) | Forma de dosagem oral de liberação prolongada, uso da mesma, método para a prevenção e/ou tratamento de distúrbios e perturbações médicas, e, processo para a fabricação de uma forma de dosagem de liberação prolongada | |
| BR0005319A (pt) | Tratamento combinado para depressão e ansiedade | |
| ES2190581T3 (es) | 2-aminotetralina opticamente activa, procedimiento para su preparacion y composiciones farmaceuticas que la contienen, activa en la prevencion y tratamiento de shock septico. | |
| MXPA02008998A (es) | Tratamiento de trastornos relacionados con el sistema serotonergico. | |
| PL425832A1 (pl) | Genisteina oraz jej kompozycja do zastosowania w leczeniu choroby Alzheimera | |
| BR0108221A (pt) | Utilização de um antagonista alpha -2b- adrenoceptor seletivo para a manufatura de um preparado farmacêutico e processo para o tratamento ou prevenção de uma enfermidade mediada pelo alfa-2b-adrenoceptor em um mamìfero |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A(S) 8A E 9A ANUIDADE(S) |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE A 8.6, DA RPI 2103 DE 26/04/2011. |